mtm laboratories Announces the European Launch of CINtec(R) PLUS - Gilde Healthcare

mtm laboratories Announces the European Launch of CINtec(R) PLUS

March 8, 2010

Powerful new biomarker combination for cervical cancer screening 

mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.*

CINtec® PLUS combines the p16 biomarker, widely validated for diagnostic purposes, with the proliferation marker Ki-67. By combining these two markers in a single diagnostic test, CINtec® PLUS provides both high sensitivity and high specificity for detecting high-grade cervical disease. The performance of this test for highly accurate detection of pre-cancerous cervical lesions has been demonstrated in three clinical trials conducted in over 30,000 women across Europe. In these studies, CINtec® PLUS was demonstrated to have significant clinical utility across a wide range of applications in cervical cancer screening and management.

“The combination of both high sensitivity and specificity in a single test is what sets CINtec® PLUS apart from currently available diagnostic tests”

said Robert Silverman, CEO of mtm laboratories,

“What this means for patients and clinicians is that early stage disease can be identified accurately in time for effective medical intervention. In comparison to the currently available technologies, CINtec® PLUS will minimize over or under diagnosis.”

CINtec® PLUS is the newest in a line of diagnostic and screening tests using the p16 biomarker that have been developed by mtm laboratories. CINtec® Histology and CINtec® Cytology are already marketed in Europe and were launched in 2007.
 
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023